The information on this website is intended to provide scientific information about Alkermes products and areas of therapeutic interest. Information may include data on investigational uses of approved or unapproved drugs for which safety and effectiveness have not been established. There is no guarantee that such uses will receive health authority approval and Alkermes does not recommend or suggest use of its medicines in a manner inconsistent with approved labeling.

This section includes selected Alkermes abstracts, posters or oral presentations, which have been accepted for congress presentations in the last 2 years. The content contained in this section is subject to congress copyright permissions.

US Psych Congress Annual
September 17th – 21st 2025, San Diego, CA
Explore materials from this congress
PLEASE NOTE: Materials will be available on a rolling basis after individual embargoes are lifted. Audio abstracts are generated using text-to-speech software and contain an audio version of the abstract that was submitted and accepted as part of the official conference materials.
Bipolar Disorder
Schizophrenia
POSTER
Real-World Impact of Olanzapine and Samidorphan on Rates of Relapse Among Young Adults With Schizophrenia or Bipolar I Disorder
AUTHOR(S)

Andrew J. Cutler, MD,1,2 Hemangi R. Panchmatia, MSc,3 Alejandro G. Hughes, MPH,4 Michael J. Doane, PhD,3 Hara E. Oyedeji, CRNP, MS,5 Rakesh Jain, MD6

Embargo date: 09-19-2025 Embargo time: 12:00 PDT
Bipolar Disorder
Schizophrenia
Bipolar Disorder
POSTER
Real-World Comparison of Olanzapine/Samidorphan vs Olanzapine: An Assessment of Treatment Patterns and Acute Care Events Among Patients With Bipolar I Disorder
AUTHOR(S)

Rakesh Jain, MD,1 Hemangi R. Panchmatia, MSc,2 Alejandro G. Hughes, MPH,3 Michael J. Doane, PhD,2 Craig Chepke, MD,4 Andrew J. Cutler, MD5,6 

Embargo date: 09-19-2025 Embargo time: 12:00 PDT
Bipolar Disorder
Schizophrenia
POSTER
Real-World Comparison of Olanzapine/Samidorphan vs Olanzapine: An Assessment of Treatment Patterns and Acute Care Events Among Patients With Schizophrenia
AUTHOR(S)

Andrew J. Cutler, MD,1,2 Hemangi R. Panchmatia, MSc,3 Alejandro G. Hughes, MPH,4 Michael J. Doane, PhD,2 Craig Chepke, MD,5 Rakesh Jain, MD6 

Embargo date: 09-19-2025 Embargo time: 12:00 PDT
Schizophrenia
Bipolar Disorder
Schizophrenia
POSTER
Olanzapine and Samidorphan in Adults With Schizophrenia or Bipolar I Disorder: Updated Review of Clinical Data
AUTHOR(S)

Leslie Citrome, MD, MPH,1 Christoph U. Correll, MD,2-5 Roger S. McIntyre, MD,6 Mark S. Todtenkopf, PhD,7 Christina Arevalo, MS,7 James A. McGrory, PhD,8 David McDonnell, MD8

Embargo date: 09-19-2025 Embargo time: 12:00 PDT
Bipolar Disorder
Schizophrenia
Bipolar Disorder
Schizophrenia
ENCORE POSTER
Safety, Tolerability, and Durability of Treatment Effect of Olanzapine and Samidorphan: A Patient Subgroup Analysis of a 4-Year Open-Label Study
AUTHOR(S)

Jacob S. Ballon, MD, MPH,1 Christina Arevalo, MS,2 Martin Dunbar, PhD,2 Alexandra Lovett, MD,2 David McDonnell, MD,3 Christoph U. Correll, MD4-7

Embargo date: 09-19-2025 Embargo time: 12:00 PDT
Bipolar Disorder
Schizophrenia
Bipolar Disorder
Schizophrenia
ENCORE POSTER
Lipid and Glycemic Profile of Olanzapine and Samidorphan: A Patient Subgroup Analysis of a 4-Year Open-Label Study
AUTHOR(S)

Jacob S. Ballon, MD, MPH,1 Christina Arevalo, MS,2 Alexandra Lovett, MD,2 Christoph U. Correll, MD3-6

Embargo date: 09-19-2025 Embargo time: 12:00 PDT
Bipolar Disorder
Schizophrenia
Schizophrenia
ENCORE POSTER
Treatment Patterns and Healthcare Resource Utilization of Patients Early in Schizophrenia Illness Initiating Aripiprazole Lauroxil Versus Oral Aripiprazole: A Retrospective Claims-Based Study
AUTHOR(S)

John M. Kane,1 Regina Grebla,2 Michael J. Doane,2 Andrea B. Barthel,3 Chenxue Liang,3 Zhengfan Wang,3 Elizabeth S. Nagelhout,3 Lauren N. Strand2

Embargo date: 09-19-2025 Embargo time: 12:00 PDT
Schizophrenia
Sleep-wake disorders
ENCORE POSTER
Matched Analysis Assessing the Clinical and Humanistic Burden of Narcolepsy Using the US National Health and Wellness Survey
AUTHOR(S)

Kiran P. Maski,1 Michael J. Doane,2 M. Janelle Cambron-Mellott,3 Shakiba Eslamimehr,3 Adam Jauregui,3 Wilbur P. Williams, III2

Embargo date: 09-19-2025 Embargo time: 12:00 PDT
Sleep-wake disorders
Sleep-wake disorders
ENCORE POSTER
Patient Perspectives on Journey to Diagnosis, Symptoms, and Burden of Idiopathic Hypersomnia From Qualitative Interviews
AUTHOR(S)

Michael J. Doane,1 Meaghan O’Connor,2 Miranda Lauher-Charest,2 Laura Tesler Waldman,2 Wilbur P. Williams, III1

Embargo date: 09-19-2025 Embargo time: 12:00 PDT
Sleep-wake disorders